In brief
- A systematic review and meta-analysis published October 11 in Neuropsychopharmacology aggregates six randomized trials with 286 participants.
- MDMA-assisted therapy reduces PTSD symptoms more effectively than controls in the short term, with an effect size of g = −0.71.
- The authors rate the overall certainty as low, urging caution due to participant expectations and functional unblinding.
A research team led by the University of Pennsylvania, including Pim Cuijpers and David Yaden, has published a “living” systematic review of MDMA-assisted therapy for post-traumatic stress disorder (PTSD). This is an open-ended tool designed to evolve: it will be updated with each new trial and keeps its data transparent for public review.
What is a “living” review and what does it include?
Traditional reviews become outdated as soon as they are published—a significant drawback in a rapidly evolving field. This project is structured as an open resource, featuring a database and online dashboard (sypres.io) that will continue to expand. The initial version includes six randomized trials totaling 286 participants. All six were sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), a fact the authors explicitly note and which should be kept in mind when reviewing the results.
What the data shows
The primary model compares PTSD symptoms against control groups using a random-effects meta-analysis. MDMA therapy achieved a greater reduction in symptoms, with a standardized mean difference of g = −0.71. It also increased the proportion of treatment responders (risk ratio of 1.35) and those who achieved remission (risk ratio of 2.25) compared to placebo. The team also explored whether dosage variables accounted for some of the differences between studies.
According to the Cochrane risk-of-bias assessment, most trials are considered low risk. However, the authors add that this tool does not adequately capture issues specific to this field: participant expectations, functional unblinding (when participants deduce whether they received the active substance), potential issues in study conduct, and safety. Using the GRADE method, the overall certainty is rated as “low.” Their conclusion is measured: to date, MDMA therapy is associated with short-term symptom reduction.
What this implies
This work does not replace other meta-analyses, such as the one we covered in our report on seven trials and the Harvard Review of Psychiatry, but it offers a different format: transparent, reproducible, and designed for continuous updates. Its value lies in the fact that any interested person can see the weight of each study and how the landscape shifts as new data emerges.
Low certainty does not mean the effect is false. It indicates that conclusions could change with more independent trials, long-term follow-ups, and designs that better address blinding. This context is useful for tracking the dossier the sector has brought back to the FDA, which we reviewed in Resilient’s new application. For a broader view of the topic, we have compiled material on our MDMA and empathogens page.
Source
- Sevchik et al. A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD. Neuropsychopharmacology, October 11, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
